Pancreatic islet cell regeneration and growth. Introduction.

Vinik AI

Eastern Virginia Medical School, Diabetes Institutes, Norfolk 23510.

Publication Types:
- Review
- Review, tutorial

PMID: 1449076, UI: 93080098

192

INTRODUCTION

Aaron I. Vinik, M.D., Ph.D.[1]

[1]Eastern Virginia Medical School
The Diabetes Institutes
Norfolk, Virginia 23510

This symposium, held in June 1991, was a gathering of international scientists to exchange their views on current concepts of cell growth and differentiation. Each scientist was asked to present a topic of their research related to cell growth and regeneration and to participate in a round table conference elaborating on current knowledge and sharing their experiences. By furthering this promising area of endeavor, a means of understanding ontogeny of cell development and of providing insights into tumor biology would prevail. Of prime importance was the anticipation that new information from a better understanding of the normal evolution of the pancreatic islet would generate alternative approaches to curing diabetes. This forward serves as a short introduction to the concept of pancreatic islet regeneration and the models currently in use to study the process.

DEVELOPMENTAL ORIGIN OF ISLETS DURING EMRYOGENESIS

The developing pancreas appears as a protrusion from the dorsal surface of the embryonic gut.[1] The different islet cell types appear sequentially during development *in vivo*. It therefore seems reasonable to propose that coordinated growth is dependent upon specificity of growth factors.

Islet cells *in vivo* also express several neuroectodermal antigens, for example, PGP 9.5,[2] neurone-specific enolase (NSE),[3] synaptophysin,[4] A2B5,[5] phenylethanolamine N-methyl-transferase (PNMT) and aromatic amino acid decarboxylase (AADC).[6] The endocrine cells of the GEP axis are capable of amine precursor uptake and decarboxylation and have, therefore, been given the acronym APUD.[7] The morphologic similarity of APUD cells suggested a common embryologic origin, which was believed to be the neural crest but later revised to include the neuroectoderm, or in the case of some of the endocrine cells, from the dorsal placoderm.

Studies by Ledouarin,[8] Pictet,[9] Andrew,[10] and their coworkers have cast doubt on this hypothesis, and most workers agree that these cells should be classified according to their secretory products, i.e., gastrin, somatostatin, glucagon. PP, etc. However, it is now thought that β-cells do not have APUD characteristics and are likely to be derived from gut, but express neuronal antigens such as the catecholamine biosynthetic enzyme tyrosine hydroxylase (TH).[11] The generally held belief that the neuronal characteristics of these cells indicated an ectodermal origin during mammalian embryogenesis has largely been dispelled.

During development *in vivo*, the phenotype of the mature islet cells appear sequentially. β-cells arise from progenitor cells localized in the pancreatic duct and these precursors transiently express TH while migrating away from the duct to populate a new islet. This suggests that the pancreatic duct is a source of endocrine stem cells throughout embryogenesis without the need to postulate a neuroendocrine origin. This notion is supported by the finding that the embryonic pancreatic duct *in vitro* is able to regenerate a new pancreas containing exocrine and endocrine cells expressing only peptides (mature cells), and cells containing both TH and a hormone (immature cells).[12,13]

Pancreatic Islet Cell Regeneration and Growth, Edited by A.I. Vinik
Plenum Press, New York, 1992

Teitelman has shown that pancreatic cells of endocrine origin can indeed express several neuronal antigens in addition to the peptide hormones.[11] She further showed that in the mouse embryo a primitive undifferentiated cell(s) led to sequential appearance of at least 4 different cell types containing either a hormone (e.g., glucagon), a catecholamine enzyme (tyrosine hydroxylase, TH) or combinations of these.[6] Under appropriate conditions these cells can be shown to differentiate into either neurites or adult endocrine cells. During regeneration, expression of neural antigens by developing cells was found to constitute an early phase to be replaced by the adult hormone secreting counterpart. Rosenberg and Vinik[14] have utilized a model for nesidioblastosis and shown that pancreatic ductal cells are capable of differentiating upon stimulation into adult endocrine cells capable of secreting insulin in a fully regulated manner.

ISLET CELL GROWTH AND DIFFERENTIATION

Factors which control the growth and functional maturation and differentiation of the human endocrine pancreas and gut during the fetal and post-natal periods are incompletely understood. The role of the fetal mesenchyme in epithelial cell development and differentiation appears to be important.[15-17] Possible mechanisms of action include: (i) secretion of an inducing or transforming hormonal growth factor, (ii) information exchange through cell-to-cell contact via paracrine and juxtacrine actions of locally elaborated growth factors, and (iii) production of an extracellular matrix rich in growth promoting factors. The soluble peptide growth factors are trophic substances that regulate both cell proliferation and differentiation and may be linked to islet growth.

One family of growth factors that may be implicated in islet growth are the somatomedins and their binding proteins. Insulin-like growth factors (IGFs) are important mediators of fetal and postnatal growth. Whereas these growth factors circulate (attached to binding proteins) they also act locally. Fetal rat islets release both IGF-I and IGF-II *in vitro* which may contribute to growth hormone-induced DNA synthesis.[18-21] It is apparent that the role of IGF-I, and the binding proteins, especially in the adult pancreas is far from clear. In this symposium Drs. LeRoith and Lauterio discuss aspects of IGF physiology, and LeRoith focuses upon differences in the role of the IGF's in regeneration of adult and fetal tissues. Dr. Hill emphasizes the role of the IGF's and their binding proteins in islet regeneration in the fetal pancreas at a time when the pancreas is susceptible to the influence of this particular group of growth factors. Dr. Bonner Weir also points out that in their model of islet regeneration after 90% pancreatectomy there is enhanced IGF gene expression in the ductules and certain connective tissue cells in contrast with the normal expression in capillary endothelial cells suggesting that IGFs may participate in the regeneration process after pancreatectomy in the rat.[22] Dr. Nielsen, however, contests the suggestion that the IGF's are important as pancreatic trophic factors and based upon his observations growth hormone itelf may be pertinent, at least in pregnancy, a state in which islet hypertrophy is found.

Several important glycoprotein components of extracellular matrix - the "integrins"- have also been recognized as playing a role in cell growth and differentiation. For example, fibronectin, laminin and tenascin.[23,24] Dr. Le Beau elaborates upon the role the integrins may play in cell regeneration. The role of these factors in the maintenance and replacement of a functional islet cell mass in the adult pancreas remains to be determined.

ISLET CELL PROLIFERATION IN THE POST-NATAL PERIOD

Several models designed to induce exocrine and endocrine pancreatic regeneration have been developed. In the model developed by Bonner-Weir and colleagues,[22,25] there is regeneration of both exocrine and endocrine tissue following a 90% pancreatectomy in which the increase in β–cell mass occurs as a result of the replication of existing β-cells and not necessarily because of a process of new islet formation.[22] This group have reported increased IGF-I mRNA production by capillary endothelial cells and proliferating ductules which may contribute to both endocrine and exocrine pancreas regeneration, but the precise

role of IGFs needs to be
has not been excluded.[22]

Terazono et al deve
treated with either n
aurothioglucose resulting
a substance termed *reg* p
gene.[28] Human *reg* mR
levels in gastric mucosa
expressed ectopically in
transformed, proliferativ
reg is expressed in acina
growth factor. Dr. O
regeneration, elaborates
this growth factor in isle
and Rafaeloff.

Expression of an h
tissue.[30] The significa
regeneration studied by
over a period of weeks t

A second version
colleagues,[31] deals wit
Hospital (NEDH) rats
demonstrate that tumor
with a profound reductio
that results in rapid β-
mRNA levels. Whether
high levels of *reg* mR
ongoing at a low, consti
this gene product.

Another model has
is observed in transgen
These mice, in which d
duct cell proliferation a
along the apical region
indicating that diabetes
destructive process. T
induce regeneration may

In 1982, we develo
8 weeks of age are ferti
of cell proliferation tha
hamster pancreatic duct
was observed. The m
proliferation and differ
processes were shown
an extract prepared fro
other hamsters, but thi
pancreas was administe
developments in the us
called Ilotropin.

The presence of th
been hypothesized but
reviews the current kn
carried out to further d
the release of a variety
and differentiation of
with factors important i
possible mechanism of
also discussed.

role of IGFs needs to be elucidated and the possibility that other growth factors participate has not been excluded.[22]

Terazono et al developed a model in which 90% pancreatectomized rats or mice are treated with either nicotinamide, (a poly ADP-ribose synthetase inhibitor), or aurothioglucose resulting in exocrine and endocrine cell regeneration, and the appearance of a substance termed *reg* protein.[26,27] The gene encoding this protein has been termed the *reg* gene.[28] Human *reg* mRNA has been detected predominantly in the pancreas, and at lower levels in gastric mucosa and in the kidney.[29] *Reg* gene protein has also been found to be expressed ectopically in colon and rectal tumors,[29] linking enhanced *reg* expression to the transformed, proliferative state, at least for some cell types. Current evidence suggests that *reg* is expressed in acinar tissue and not regenerating islets. It may therefore be a paracrine growth factor. Dr. Okamoto, who pioneered the work on Reg gene and pancreatic regeneration, elaborates here upon his new findings. The controversy over the relevance of this growth factor in islet regeneration in other models is further discussed by Drs. Newgard and Rafaeloff.

Expression of an homologous gene, termed *rig*, has been identified in insulinoma tissue.[30] The significance of these genes remains to be determined. In both models of regeneration studied by Okamoto and colleagues,[26,27,29] islet size increased above normal over a period of weeks to months.

A second version of the 90% pancreatectomized rat model studied by Newgard and colleagues,[31] deals with *reg* expression in insulinoma-bearing New England Deaconess Hospital (NEDH) rats relative to normal controls and following tumor resection. They demonstrate that tumor implantation causes a sharp reduction in *reg* expression associated with a profound reduction in non-tumor islet size and that removal of the tumor, a maneuver that results in rapid β-cell proliferation, results in a large but transient induction in *reg* mRNA levels. Whether *reg* protein is β-cytotrophic is still an open question. The fact that high levels of *reg* mRNA are present in normal animals, in which β-cell replication is ongoing at a low, constitutive rate, are seemingly at odds with a growth-promoting role for this gene product.

Another model has been suggested by Dr. Sarvetnick[32] in which a regenerative process is observed in transgenic mice expressing Interferon-gamma in their pancreatic β-cells. These mice, in which diabetes ensues following immunodestruction of their β-cells, show duct cell proliferation and the appearance of more primitive neuroendocrine progenitor cells along the apical regions of the ducts. Dr. Sarvetnick discusses her most recent findings indicating that diabetes may not develop provided that the regenerative process outstrips the destructive process. This, we believe, is an important principle whereby an approach to induce regeneration may not be unreasonable in our quest for a cure for diabetes.

In 1982, we developed a unique model for islet regeneration in hamsters.[33,34] Hamsters 8 weeks of age are fertile, considered to be adult animals and respond better to the induction of cell proliferation than do older animals.[33,34] By producing partial obstruction of the hamster pancreatic duct by cellophane wrapping, new islet formation from ductal elements was observed. The mechanism by which partial obstruction in our model induces cell proliferation and differentiation is unknown. Using a parabiotic experimental design, these processes were shown to be mediated by paracrine and/or autocrine mechanisms.[30] Indeed, an extract prepared from a wrapped pancreas exhibited trophic activity when injected into other hamsters, but this was not observed when an extract prepared from a non-wrapped pancreas was administered. Drs. Rosenberg and Vinik review the data and the more recent developments in the use of a cytosol extract, containing the growth factor which we have called Ilotropin.

The presence of this specific growth factor, Ilotropin, in the β-cell cytosol extract has been hypothesized but the identity of the peptide had not been established. Dr. Pittenger reviews the current knowledge of the nature of the growth factor and the studies he has carried out to further define its characteristics. However, cellophane wrapping may initiate the release of a variety of growth factors that contribute to the coordinated, timely growth and differentiation of ductal cells. These possibilities and other factors that may be shared with factors important in the nervous system are highlighted by members of the faculty. The possible mechanism of action of the various factors as well as therapeutic applications are also discussed.

GROWTH FACTOR(S) AND NEOPLASIA

A great deal of interest is now being focused upon the factors responsible for initiation of growth, increase in cell number and size, differentiation into adult endocrine cells, growth cessation and cell maintenance.[36,37] The coincidental findings that the multiple endocrine neoplasia, type 1 syndrome (MEN-1) (combined occurrence of tum rs f the pituitary, pancreas and parathyroid glands) is associated with the loss of alleles on chromosome 11,[38,39] the same chromosome on which the insulin gene has been located;[40] the finding of parathyroid mitogenic activity in the plasma of patients with MEN-1;[36,37] and evidence that patients with MEN-1 might also secrete mitogenic factors for pancreatic islet-cells into plasma,[41] suggests a role for genetically determined circulating growth factors in the 'growth initiation' of these tumors.

It is apparent, therefore, that the conference was timeous and that the information pertinent to our appreciation of cell growth and differentiation is relevant to a possible cure for diabetes as well as a clearer understanding of factors that may be involved in pancreatic tumor formation. Conceptually, these conditions represent the two ends of a spectrum - diabetes with endocrine cell failure and endocrine neoplasia with unbridled cell growth.

REFERENCES

1. R.L. Pictet and J.W. Rutter, Development of the embryonic endocrine pancreas, *in:* "Handbook of Physiology," D.F. Steiner and M. Frenkel, eds., Washington D.C., American Physiological Society (1972).
2. K.J. Thompson, J.F. Doran, P. Jackson, A.P. Dhillon, and J. Rode, PGP 9.5: a new marker for vertebrate neurons and endocrine cells, Brain Res. 278:224-28 (1983).
3. Polak, et al. Neuron-specific enolase, a marker for neuro-endocrine cells, *in:* Evolution and Tumor Pathology of the Neuro-endocrine System. Elsevier, New York (1984).
4. B. Weidenmann, W.W. Franke, C. Kuhn, R. Moll, and V.E. Gould, Synaptophysin: a marker protein for neuro-endocrine cells and neoplasms, Proc Natl Acad Sci USA. 83:3500-04 (1986).
5. G.S. Eisenbarth, K. Shimizu, M.A. Bowring, and S. Wells, Expression of receptors for fetanus toxin and monoclonal antibody A_2B_2 by pancreatic islet cells, Proc Natl Acad Sci USA. 79:5066-70 (1982).
6. G. Teitelman, T.H. Joh, and D.J. Reis, Transformation of catecholaminergic precursor into glucagon (A) cells in mouse embryonic pancreas, Proc Natl Acad Sci USA. 78:5225-29 (1991).
7. A.G.E. Pearse, Common cytochemical and ultrastructural characteristics of cells producing polypeptide hormones (the APUD series) and their relevance to thyroid and ultimobronchial C cells and calcitonin, Proc R Soc Lond (Biol). 170:71 (1968).
8. N.M. LeDouarian and M.A. Teillet, The migration of neural crest cells to the wall of the digestive tract in avian embryo, J Embryol Exp Morphol. 30:31 (1973).
9. R.L. Pictet, L.B. Rall, P. Phelps, and W.J. Rutter, The neural crest and the origin of the insulin-producing and other gastrointestinal hormone-producing cells, Science. 191:191 (1967).
10. A. Andrew, An experimental investigation into the possible neural crest origin of pancreatic APUD (islet) cells, J Embryol Exp Morphol. 35:577 (1976).
11. G. Teitelman and J.K. Lee, Cell lineage analysis of pancreatic islet cell development: Glucagon and insulin cells arise from catecholaminergic precursor present in the pancreatic duct, Devel Biol. 121:454-56 (1987).
12. G. Teitelman, J. Lee, and D.J. Reis, Differentiation of prospective mouse pancreatic islet cells during development *in vitro* and during regeneration, Dev Biol. 120:425-33 (1987).
13. R.W. Dudek and I.E. Lawrence, Morphologic evidence of interaction between adult ductal epithelium of pancreas and fetal foregut mesenchyme, Diabetes. 37:891-900 (1988).
14. L. Rosenberg, W.P. Duguid, and A.I. Vinik, Cell proliferation in the pancreas of the Syrian golden hamster, Dig Dis Sci. 32:1185 (1987).
15. R.L. Pictet, L. Rail, M. de Gasparo, and W.J. Rutter, Regulation of differentiation of endocrine cells during pancreatic development in-vitro, *in:* "Early diabetes in early life," R.A. Camerini-Davalos and H.S. Cole, eds., Academic Press, New York (1975).
16. B.S. Spooner, H.I. Cohen, and J. Faubion, Development of the embryonic mammalian pancreas: The relationship between morphogenesis and cytodifferentiation, Dev Biol. 61:119 (1977).
17. R. Montesano, P. Mouron, M. Amherdt, and L. Orci, Collagen matrix promotes reorganization of pancreatic endocrine cell monolayers into islet-like organoids, J Cell Biol. 97:935 (1983).
18. I. Sweene and D.J. Hill, Growth hormone regulation of DNA replication, but not insulin production, is partly mediated by somatomedin C/insulin-like growth factor-I in isolated pancreatic islets from adult rats, Diabetologia. 32:191-97 (1989).
19. D.J. Hill, A. Frazer, I. Swe, P.K. Wirdnam, and R.D.G. Milner, Somatostatin-C in human fetal pancreas, Diabetes. 36:465 (1987).
20. A. Rabinovitch, C. Quigl activity (an insulin-li monolayer cultures,
21. J.M. Bryson, B.E. Tuch, pancreas in culture, J
22. J.S. Brockenbrough, G.C. 90% pancreatectomy
23. M.J. Politis, Exogeneous Reconstr Surg. 83:22
24. R. Chiquet-Ehrismann, E protein involved in t (1986).
25. F. Smith, K. Rosen, L. Vi is localized to capill
26. K. Terazono, H. Yamamo gene activated in reg
27. K. Terazono, Y. Uchiyam Expression of *reg* pr secretory granules, D
28. T. Watanabe, H. Yonekur of human *reg* gene a (1990).
29. C. Miyaura, et al, Express cell mass, Mol Endo
30. S. Takasawa, K. Yamamo Diabetes. 35:1178 (1
31. L. Chen, M. Appel, T. Al Regulating Islet Rege
32. N. Sarvetnick, Islet cell d (abstract) (1991).
33. L. Rosenberg, W.P. Dugu diabetes in the Syria
34. L. Rosenberg and A.I. Vi paracrine and/or auto
35. L. Rosenberg and A.I. Vi from the "wrapped"
36. M.L. Brandi, G.D. Aurba with familial multipl
37. S.J. Marx, K. Sakaguchi, in plasma from mem Endocrinol Metab. 6
38. C. Larsson, B. Skogseid, 1 gene maps to chro
39. R.V. Thakker, P. Bouloux O'Riordan, Associati alleles on chromoso
40. D. Owerbach, G.I. Bell, arm of chromosome
41. M.K. McLeod, A.M. Tute mitogenic factor in p November 15-18, 19

ctors responsible for initiation
) adult endocrine cells, growth
igs that the multiple endocrine
:e of tumors of the pituitary,
ss of alleles on chromosome
been located;[40] the finding of
MEN-1;[36,37] and evidence that
for pancreatic islet-cells into
g growth factors in the 'growth

ous and that the information
n is relevant to a possible cure
may be involved in pancreatic
the two ends of a spectrum -
ith unbridled cell growth.

pancreas, *in:* "Handbook of
, American Physiological Society

P 9.5: a new marker for vertebrate

ills, *in:* Evolution and Tumor
1984).
naptophysin: a marker protein for
3:3500-04 (1986).
i of receptors for fetanus toxin and
ad Sci USA. 79:5066-70 (1982).
nergic precursor into glucagon (A)
5225-29 (1991).
cs of cells producing polypeptide
timobronchial C cells and calcitonin,

; to the wall of the digestive tract in

the origin of the insulin-producing
191 (1967).
st origin of pancreatic APUD (islet)

l development: Glucagon and
; pancreatic duct, Devel Biol.

ase pancreatic islet cells during
-33 (1987).
between adult ductal epithelium of
988).
ancreas of the Syrian golden

ferentiation of endocrine cells during
" R.A. Camerini-Davalos and H.S.

onic mammalian pancreas: The
/ Biol. 61:119 (1977).
promotes reorganization of
Cell Biol. 97:935 (1983).
on, but not insulin production, is
i isolated pancreatic islets from adult

tostatin-C in human fetal pancreas,

20. A. Rabinovitch, C. Quigley, T. Russell, Y. Patel, and D.H. Mintz, Insulin and multiplication stimulating activity (an insulin-like growth factor) stimulate islet β-cell replication in neonatal rat pancreatic monolayer cultures, Diabetes. 31:160 (1982).
21. J.M. Bryson, B.E. Tuch, and R.C. Baxter, Production of insulin-like growth factor-II by human fetal pancreas in culture, J Endocrinol. 121:367-73 (1989).
22. J.S. Brockenbrough, G.C. Weir, and S. Bonner-Weir, Discordance of exocrine and endocrine growth after 90% pancreatectomy in rats, Diabetes. 37:232-36 (1988).
23. M.J. Politis, Exogeneous laminin induces regenerative changes in traumatized sciatic and optic nerve, Plas Reconstr Surg. 83:228-35 (1989).
24. R. Chiquet-Ehrismann, E.J. Mackie, C.A. Pearson, and T. Sakakura, Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis, Cell. 47:131-39 (1986).
25. F. Smith, K. Rosen, L. Villa-Kamoroff, et al, Enhanced IGG-I gene expression in regenerating rat pancreas is localized to capillaries and proliferating ductules, Diabetes. 39(Suppl 1):66A (1990).
26. K. Terazono, H. Yamamoto, S. Takasawa, K. Shiga, Y. Yonemura, Y. Tochino, and H. Okamoto, A novel gene activated in regenerating islets, J Biol Chem. 262:2111 (1988).
27. K. Terazono, Y. Uchiyama, M. Ide, T. Watanabe, H. Yonekura, H. Yamamoto, and H. Okamoto, Expression of *reg* protein in rat regenerating islets and its co-localization with insulin in beta cell secretory granules, Diabetologia. 33:1 (1990).
28. T. Watanabe, H. Yonekura, K. Terazono, H. Yamamoto, and H. Okamoto, Complete nucleotide sequence of human *reg* gene and its expression in normal and tumoral tissues, J Biol Chem. 265:7432-39 (1990).
29. C. Miyaura, et al, Expression of *reg*/PSP, a pancreatic exocrine gene: Relationship to changes in islet β-cell mass, Mol Endocrinol. (1991, in press).
30. S. Takasawa, K. Yamamoto, K. Terazono, and H. Okamoto, Novel gene activated in rat insulinoma, Diabetes. 35:1178 (1986).
31. L. Chen, M. Appel, T. Alam, C. Miyaura, A. Sestak, J. O'Neil, R. Unger, and C. Newgard, Factors Regulating Islet Regeneration in the Post-Insulinoma NEDH Rat.
32. N. Sarvetnick, Islet cell destruction and regeneration in IFN-γ transgenic mice, J Cell Biochem. CB019:49 (abstract) (1991).
33. L. Rosenberg, W.P. Duguid, R.A. Brown, and A.I. Vinik, Induction of islet cell proliferation will reverse diabetes in the Syrian golden hamster, Diabetes. 37:334 (1988).
34. L. Rosenberg and A.I. Vinik, Regulation of pancreatic islet growth and differentiation: Evidence for paracrine and/or autocrine growth factor(s), Clin Res. 38:271A (1990).
35. L. Rosenberg and A.I. Vinik, In vitro stimulation of hamster pancreatic duct growth by an extract derived from the "wrapped" pancreas, (submitted for publication).
36. M.L. Brandi, G.D. Aurbach, L.A. Fitzpatrick, et al, Parathyroid mitogenic activity in plasma from patients with familial multiple endocrine neoplasia type 1, N Engl J Med. 314:1287-93 (1986).
37. S.J. Marx, K. Sakaguchi, J. Green, G.D. Aurbach, and M.L. Brandi, Mitogenic activity on parathyroid cells in plasma from members of a large kindred with multiple endocrine neoplasia Type 1, J Clin Endocrinol Metab. 67:149-53 (1988).
38. C. Larsson, B. Skogseid, K. Oberg, Y. Nakamura, and M. Nordenskjold, Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma, Nature. 332:85-87 (1988).
39. R.V. Thakker, P. Bouloux, C. Wooding, K. Chotai, P.M. Broad, N.K. Spurr, G.M. Besser, and J.L. O'Riordan, Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11, N Engl J Med.321:218-24 (1989).
40. D. Owerbach, G.I. Bell, W.J. Rutter, J.A. Brown,and T.B. Shows, The insulin gene is activated on the short arm of chromosome 11 in humans, Diabetes. 30:267-70 (1981).
41. M.K. McLeod, A.M. Tutera, N.W. Thompson, and A.I. Vinik, Evidence for a pancreatic islet-cell mitogenic factor in patients with MEN-1, Association for Academic Surgery, Louisville, Kentucky, November 15-18, 1989.